{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OAV101",
    "query": {
      "intervention": "OAV101"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T04:32:46.658Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05089656",
      "title": "Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "OAV101",
          "type": "GENETIC"
        },
        {
          "name": "Sham control",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 126,
      "start_date": "2022-02-01",
      "completion_date": "2025-04-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-07T04:32:46.658Z",
      "location_count": 6,
      "location_summary": "Farmington, Connecticut • Chicago, Illinois • Strasburg, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Strasburg",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05089656"
    },
    {
      "nct_id": "NCT05386680",
      "title": "Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "OAV101",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 27,
      "start_date": "2023-01-12",
      "completion_date": "2024-11-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-07T04:32:46.658Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Norfolk, Virginia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05386680"
    },
    {
      "nct_id": "NCT05335876",
      "title": "Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy (SMA)"
      ],
      "interventions": [
        {
          "name": "onasemnogene abeparvovec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "0 Years to 100 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-12-19",
      "completion_date": "2031-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-07T04:32:46.658Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05335876"
    },
    {
      "nct_id": "NCT04851873",
      "title": "Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "OAV101",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-09-08",
      "completion_date": "2023-06-13",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-09-07T04:32:46.658Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04851873"
    }
  ]
}